Dermatological Disorders

Fish Pedicure Causes Woman to Lose Toenails

July 16, 2018

Dermatologists should be aware of potential skin, nail problems tied to fish pedicures

Topical JAK Inhibitor Granted Fast Track Designation for Alopecia Areata

By July 09, 2018

ATI-502 is a topical Janus Kinase (JAK) 1/3 inhibitor.

High Patient Burden With Moderate-to-Severe Atopic Dermatitis

July 06, 2018

Many patients with moderate/severe atopic dermatitis have inadequate disease control

Novel Treatment for Primary Axillary Hyperhidrosis Gets FDA Approval

By June 29, 2018

The approval was supported by Phase 3 data from the ATMOS-1 and ATMOS-2 trials which evaluated the absolute change from baseline in sweat production after treatment with Qbrexza, and the proportion of patients who achieved ≥4-point improvement from baseline in their sweating severity (as measured by the Axillary Sweating Daily Diary [ASDD]).

Idaho Pharmacists Able to Prescribe Meds for Several Conditions on July 1

By June 27, 2018

The new rule allows pharmacists to prescribe medications for cold sores, seasonal influenza, strep throat, and urinary tract infections, as well as statins for patients with diabetes.

Oral Acne Treatments

June 26, 2018

Oral medications for the treatment of acne including dosing for antibiotics, retinoids, and contraceptives.

Topical Acne Treatments

June 26, 2018

A chart of topical acne medications for the use in children and adults including available strengths.

Treatment for Necrobiosis Lipoidica Gets Orphan Drug Designation

By June 22, 2018

In a press release Dr. David Young, CEO of Processa said "We plan to begin our clinical studies in 2018 and to accelerate the development of PCS499 in order to provide clinical benefit to [necrobiosis lipoidica] patients as soon as possible."

Treatment of Hidradenitis Suppurativa with SAPHO Syndrome: A Case Review

By June 21, 2018

The male patient presented in 2009 with a "3-year history of multiple interconnecting comedones in the axilla and inguinal regions, as well as scarring from previous lesions."

Topical Rapamycin Effective for TSC-Related Facial Angiofibromas

June 11, 2018

The researchers observed clinically meaningful and statistically significant improvement in facial angiofibromas for 1 and 0.1% rapamycin versus vehicle only, and for 1 vs 0.1% rapamycin; most of the improvement was seen in the first month.

Rituxan Approved for Moderate to Severe Pemphigus Vulgaris

By June 08, 2018

The approval was based on data from the Ritux 3 trial (N=90) which compared rituximab + short-term oral prednisone (Ritux 3 regimen) to oral prednisone alone as a first-line treatment for patients with newly diagnosed moderate to severe PV.

Physician Sued for Negligence After Relying on Patient's Self-Diagnosis

By June 04, 2018

This month we look at the issue of whether a physician can be liable for relying on information provided by the patient.

New Biologic Treatment Option Approved for Patients With Plaque Psoriasis

By May 29, 2018

The expanded approval was supported by findings from a Phase 3 clinical program (CIMPASI-1, CIMPASI-2, and CIMPACT), which enrolled ~1000 patients who were biologic-naive or biologic-experienced.

Topically-Applied Gene Tx Fast-Tracked for Dystrophic Epidermolysis Bullosa

By May 25, 2018

KB103 is a replication-defective, non-integrating viral vector that utilizes the Company's STAR-D platform to deliver functional human COL7A1 genes directly to the patients' dividing and non-dividing skin cells.

Certolizumab Looks Promising for Moderate-to-Severe Psoriasis

May 25, 2018

The drug also maintained results at 48 weeks for patients who were re-randomized to placebo or continued with certolizumab. Reported adverse events were similar to those previously reported with the anti-tumor necrosis factor class.

Research Lacking on Platelet-Rich Tx for Facial Aesthetics, Alopecia

May 25, 2018

The researchers identified 7 studies that used platelet-rich plasma alone for facial rejuvenation, 7 in combination with fat grafting, 2 for treatment of acne scarring, and 6 for treatment of androgenic alopecia.

Restylane Lyft Approved to Correct Volume Deficit in the Dorsal Hand

By May 23, 2018

The approval was based on a multicenter, randomized, evaluator-blinded, split-hand study (N=89) which showed that treatment with Restylane Lyft resulted in a clinically meaningful improvement in the correction of volume deficits of treated hands for up to 6 months.

Taltz Label Updated to Include Data on Psoriasis Affecting Genital Area

By May 22, 2018

The approval was based on data from a randomized, placebo-controlled trial that included 149 adults with plaque psoriasis who had a minimum body surface area (BSA) involvement of 1%, a static Physician Global Assessment (sPGA) score of ≥3 (moderate psoriasis), a sPGA of Genitalia score of ≥3 (moderate psoriasis involving the genital area), who failed to respond to or were intolerant of at least one topical therapy used for the treatment of psoriasis affecting the genital area, and who were candidates for phototherapy and/or systemic therapy.

Sustained Use of Oxymetazoline Cream Efficacious for Rosacea

May 17, 2018

The researchers found that 8.2% of patients reported treatment-emergent adverse events (TEAEs), the most common were application site dermatitis, paresthesia, pain, and pruritus. Several authors disclosed financial ties to Allergan, which is a manufacturer of oxymetazoline.

Positive Results for Dupilumab in Teen Atopic Dermatitis Trial

By May 16, 2018

The primary endpoint was the proportion of patients with an IGA score of 0 (clear) or 1 (almost clear) at Week 16.

Topical Treatment for Epidermolysis Bullosa Gets FDA's Rare Pediatric Designation

By May 16, 2018

A previous Phase 2 trial of 17 patients with EBS showed that 60% of those treated with diacerein cream experienced at least a 40% reduction in blistering after 4 weeks vs 18% on vehicle.

Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Causes, Treatment Investigated

By May 15, 2018

The multicenter retrospective study (N=377) was conducted to investigate the causes, treatment protocols, and mortality rates of US adults with SJS/TEN.

Can 3-D Printing Create Temporary Prosthesis, Cut Out Prosthodontist?

May 15, 2018

Evaluators were able to match the correct 3-D nose to the corresponding volunteers' photographs in 171 of 175 photographs (97.7%).

Shower Cream, Body Lotion Combo Improves Atopic Dry Skin

May 15, 2018

Both products reduced clinical dryness, roughness, redness, cracks, tingling, and itch, according to the dermatologist, and increased feelings of soothing, smoothness, and softness, according to the participants.

Teledermatology Could Expedite Care for Suspected Skin Cancer

May 14, 2018

The researchers found that the mean time to clinical resolution was 9 days with teledermoscopy referral, compared with 35 days with usual care alone.

Adverse Effect of Osteoporosis Drug May Help Treat Hair Loss

By May 11, 2018

Researchers found that a non-immunosuppressant drug originally designed to treat osteoporosis (WAY-316606) targeted the same mechanism by antagonizing SFRP1, and after treating hair follicles with WAY-316606 for 6 days, the authors found enhanced human hair growth.

Eskata Now Available to Treat Raised Seborrheic Keratoses

By May 07, 2018

Eskata is a high-concentration hydrogen peroxide-based topical solution intended for in-office application.

Combo Therapy Appears Safe, Effective for Severe Inflammatory Acne

By May 07, 2018

Treatment with the combination gel + oral doxycycline was associated with a 66.2% reduction in inflammatory lesions, a 58.7% reduction in non-inflammatory lesions, and a 62.6% reduction in total lesions at Week 12 vs baseline (P <.0001).

Psoriasis Negatively Affects Patient Sleep Quality

May 07, 2018

Based on the Pittsburgh Sleep Quality Index, 53.9% of patients with psoriasis were poor sleepers versus 21.9% of controls. Itch symptoms were significantly associated with all sleep-related outcomes.

HBV Reactivation Examined in Patients Treated With TNF Antagonists

By May 03, 2018

The authors examined data from 8887 individuals who began TNF antagonist treatment for an autoimmune disease from 2001 through 2010 and were followed through 2012; 52% of these patients were screened for HBV before treatment.